Using PSMA-PET imaging to predict prostate cancer progression and treatment response
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
PHASE3 · Centre hospitalier de l'Université de Montréal (CHUM) · NCT03594760
This study is testing a new imaging method called PSMA-PET to see if it can better detect advanced prostate cancer and help doctors make better treatment decisions for patients.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) (other) |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT03594760 on ClinicalTrials.gov |
What this trial studies
This clinical trial focuses on utilizing a novel imaging technique called PSMA-PET to assess metastatic prostate cancer in patients. By injecting a tracer (18F-DCFPyL), the study aims to evaluate the effectiveness of this imaging method in detecting metastases more accurately than traditional imaging techniques. The goal is to map the metastatic state of prostate cancer to better guide treatment decisions and improve patient outcomes. The trial will involve patients being treated at the Centre hospitalier de l'Université de Montréal who require a PSMA-PET scan as part of their care.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with prostate cancer who are being treated at CHUM and have a physician's request for a PSMA-PET scan.
Not a fit: Patients who are claustrophobic or unable to complete the imaging procedure will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate treatment planning and improved outcomes for patients with metastatic prostate cancer.
How similar studies have performed: Other studies have shown promising results with PSMA-PET imaging, indicating its potential effectiveness in clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with prostate cancer, being followed and treated at CHUM, whose treating physician at CHUM has requested a PSMA-PET scan. Exclusion Criteria: * Claustrophobia/inability to complete imaging procedure.
Where this trial is running
Montreal, Quebec
- Centre Hospitalier de l'université de Montréal — Montreal, Quebec, Canada (RECRUITING)
Study contacts
- Principal investigator: Daniel Juneau, MD — Centre hospitalier de l'Université de Montréal (CHUM)
- Study coordinator: Daniel Juneau, MD
- Email: daniel.juneau@umontreal.ca
- Phone: 1-514-890-8180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer